search
Back to results

Weight Loss Clinical Decision Support (BMI-CDS)

Primary Purpose

Diabetes Mellitus, Type 2, Obesity

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
BMI-CDS
Sponsored by
HealthPartners Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Diabetes Mellitus, Type 2 focused on measuring Clinical Decision Support, Shared Decision Making, Diabetes, Metabolic Bariatric Surgery, Obesity Management, Obesity

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adults (age 18-75 years at index clinical encounter)
  • Existing diagnosis of T2DM
  • BMI ≥35 kg/m2 at index clinical encounter
  • Have an index clinical encounter with a PCC (family practice or general internal medicine physician, nurse practitioner, or physician assistant) at a randomized study clinic during a 12-month accrual period

Exclusion Criteria:

  • Prior MBS
  • Patients diagnosed with cancer (except non-melanoma skin cancer), dementia, and/or cirrhosis.
  • Pregnant or breastfeeding.
  • In long-term care, palliative care, or hospice care.

Sites / Locations

  • HealthPartners Medical GroupRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

BMI-CDS

Usual Care

Arm Description

Clinicians and their patients assigned to intervention clinics will receive shared decision support tools for weight loss management.

Clinicians and their patients assigned to control clinics will engage in the usual standard of care.

Outcomes

Primary Outcome Measures

Proportion of patients referred to an MBS program
Proportion of study-eligible patients with estimated high benefit from MBS seen in clinics with the BMI-CDS intervention will be more likely than patients seen in usual care clinics to receive a referral to MBS
Number of new prescriptions of an FDA-approved pharmaceutical for obesity management
Patients seen in clinics with the BMI-CDS intervention will be more likely than patients seen in usual care clinics to receive to receive a new prescription medication for obesity management
Change in weight trajectory during 18-month post-intervention follow-up period
The within-patient slope of weight measurements over the 18 months following the index visit will be less positive for those seen in BMI-CDS intervention versus usual care clinics.

Secondary Outcome Measures

Likelihood of patient conversation with their pcc about weight loss
Relative to patients with an index clinical encounter at usual care clinics, those with an index clinical encounter at BMI-CDS clinics will be more likely have had a conversation with their PCC about weight loss.
Intentions to engage in weight loss
Relative to patients with an index visit at usual care clinics, those with an index clinical encounter at BMI-CDS clinics will report stronger intentions to engage in weight loss.

Full Information

First Posted
December 20, 2021
Last Updated
August 11, 2023
Sponsor
HealthPartners Institute
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT05198765
Brief Title
Weight Loss Clinical Decision Support
Acronym
BMI-CDS
Official Title
Reducing Clinical Inertia in Obesity Management of Diabetes Patients in Primary Care: Cluster-Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 19, 2023 (Actual)
Primary Completion Date
January 2025 (Anticipated)
Study Completion Date
April 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HealthPartners Institute
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Despite steady increases in obesity prevalence, the more than 12 million obese U.S. adults with type 2 diabetes (T2DM) and severe obesity encounter a number of barriers to adopting effective surgical and pharmaceutical treatments, including: (a) both patients and primary care clinicians frequently underestimate the effectiveness and potential benefits of obesity treatments; and (b) both patients and clinicians typically lack access to evidence-based estimates of the patient-specific potential benefits and risks of appropriate obesity treatment options. This project addresses these important obstacles to evidence-based obesity care by providing accurate, patient-specific estimates of benefits and risks of various obesity treatment options to inform shared decision making about obesity treatment. In this project the study team will implement a scalable, web-based point-of-care decision-support intervention in primary care that provides patient-specific estimates of obesity treatment benefits and risks in a randomized trial in 40 primary care clinics with 15,810 eligible patients, and assess intervention impact on (i) appropriate active management of obesity in eligible patients, (ii) weight trajectories, and (iii) patient and clinician satisfaction with the decision support intervention.
Detailed Description
Obesity has been steadily increasing in prevalence and now affects more than 4 in 10 U.S. adults, leading to many adverse health outcomes including myocardial infarction, stroke, type 2 diabetes (T2DM), hypertension, sleep apnea, arthritis, and others. Effective surgical, pharmaceutical, and behavioral treatments for obesity are available, and the evidence to support the broad use of these treatments for obesity is very well established. However, active management of obesity defined as prescribing or referring adults with obesity for lifestyle, pharmaceutical, or surgical treatment of obesity, is greatly underused. Major underlying reasons for underutilization of effective obesity treatments include: (a) both patients and primary care clinicians (PCCs) frequently underestimate the effectiveness and potential benefits of obesity treatments; and (b) both patients and clinicians typically lack access to evidence-based, patient-specific estimates of the potential benefits and risks of appropriate patient-specific obesity treatment options. To address this problem, the study team will integrate externally validated prediction equations that estimate benefits and risk of various obesity treatment options in adults with T2DM into a widely-used and successful clinical decision support system in order to deliver appropriate patient-specific obesity treatment suggestions at the point of care. The team will implement a scalable, web-based point-of-care decision-support intervention in a randomized trial in 40 primary care clinics with 15,810 eligible patients, and assess intervention impact on the following primary outcomes: (a) appropriate referral of eligible patients for evaluation for metabolic bariatric surgery (MBS); (b) appropriate initiation of FDA-approved medications for weight loss; (c) weight trajectories; and (d) patient-reported conversations with their PCC about weight loss and intentions to engage in weight loss. In addition, the study team collect and analyze clinician-reported and patient-reported data to identify factors that may impede or facilitate broad dissemination of this intervention strategy to other care delivery settings. This innovative project will (a) provide state-of-the-art scientific evidence on obesity treatment to large numbers of obese American adults with T2DM and their PCCs at the point of care; (b) help PCCs identify appropriate patient-specific obesity treatment options; (c) implement in primary care a web-based electronic health record (EHR)-linked obesity treatment clinical decision support model that uses state-of-the-art Health Information Technology (HIT) standards, is broadly scalable, easy to update as evidence changes, and optimized for clear communication of information to patients and PCCs; and (d) improve the clinical return on ongoing massive private and public investments in outpatient health information systems.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2, Obesity
Keywords
Clinical Decision Support, Shared Decision Making, Diabetes, Metabolic Bariatric Surgery, Obesity Management, Obesity

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
10120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BMI-CDS
Arm Type
Experimental
Arm Description
Clinicians and their patients assigned to intervention clinics will receive shared decision support tools for weight loss management.
Arm Title
Usual Care
Arm Type
No Intervention
Arm Description
Clinicians and their patients assigned to control clinics will engage in the usual standard of care.
Intervention Type
Behavioral
Intervention Name(s)
BMI-CDS
Other Intervention Name(s)
Weight Loss Wizard, BMI Wizard
Intervention Description
The BMI-CDS is a sophisticated point of care shared decision support tool for patients with type 2 diabetes and high BMI. The intervention is built on existing point of care clinical decision support system that algorithmically identifies study-eligible patients and deploys patient-specific CDS output at an index visit and updated CDS all subsequent primary care office, video, and phone encounters.
Primary Outcome Measure Information:
Title
Proportion of patients referred to an MBS program
Description
Proportion of study-eligible patients with estimated high benefit from MBS seen in clinics with the BMI-CDS intervention will be more likely than patients seen in usual care clinics to receive a referral to MBS
Time Frame
Within 18 months of index visit date
Title
Number of new prescriptions of an FDA-approved pharmaceutical for obesity management
Description
Patients seen in clinics with the BMI-CDS intervention will be more likely than patients seen in usual care clinics to receive to receive a new prescription medication for obesity management
Time Frame
Within 18 months of index visit date
Title
Change in weight trajectory during 18-month post-intervention follow-up period
Description
The within-patient slope of weight measurements over the 18 months following the index visit will be less positive for those seen in BMI-CDS intervention versus usual care clinics.
Time Frame
18 months following the index visit
Secondary Outcome Measure Information:
Title
Likelihood of patient conversation with their pcc about weight loss
Description
Relative to patients with an index clinical encounter at usual care clinics, those with an index clinical encounter at BMI-CDS clinics will be more likely have had a conversation with their PCC about weight loss.
Time Frame
6 months following index visit
Title
Intentions to engage in weight loss
Description
Relative to patients with an index visit at usual care clinics, those with an index clinical encounter at BMI-CDS clinics will report stronger intentions to engage in weight loss.
Time Frame
6 months following index visit

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adults (age 18-75 years at index clinical encounter) Existing diagnosis of T2DM BMI ≥35 kg/m2 at index clinical encounter Have an index clinical encounter with a PCC (family practice or general internal medicine physician, nurse practitioner, or physician assistant) at a randomized study clinic during a 12-month accrual period Exclusion Criteria: Prior MBS Patients diagnosed with cancer (except non-melanoma skin cancer), dementia, and/or cirrhosis. Pregnant or breastfeeding. In long-term care, palliative care, or hospice care.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Patrick J O'Connor, MD
Phone
952-967-5034
Email
patrick.j.oconnor@healthpartners.com
First Name & Middle Initial & Last Name or Official Title & Degree
Heidi L Ekstrom, MA
Phone
952-967-7602
Email
heidi.l.ekstrom@healthpartners.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrick J O'Connor, MD MPH MA
Organizational Affiliation
HealthPartners Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
HealthPartners Medical Group
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55440
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Heidi L Ekstrom, MA
Email
heidi.l.ekstrom@healthpartners.com
First Name & Middle Initial & Last Name & Degree
Patrick J O'Connor, MD, MPH, MA

12. IPD Sharing Statement

Learn more about this trial

Weight Loss Clinical Decision Support

We'll reach out to this number within 24 hrs